Pierluigi Giampaolino

Prof. Pierluigi Giampaolino

Gynecology and Obstetrics Unit, Department of Public Health, School of Medicine, University of Naples Federico II, Naples, Italy

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Luigi Della CorteLuigi Della Corte
Luigi Della Corte
CFClaudia Di Filippo
Claudia Di Filippo
OGOlimpia Gabrielli
Olimpia Gabrielli
SRSabrina Reppuccia
Sabrina Reppuccia
Valentina Lucia La RosaValentina Lucia La Rosa
Valentina Lucia La Rosa
PGPierluigi Giampaolino
Pierluigi Giampaolino
Endometriosis is a chronic, inflammatory disease affecting more than 170 million women worldwide and up to 10% of women of reproductive age. As a consequence of inflammatory reaction and infiltration of anatomic structures, endometriosis can cause “pain symptoms” including dysmenorrhea, dyspareunia, dyschezia, dysuria, and chronic pelvic pain. In this review, we summarized the impact of endometriosis on quality of life in all its aspects including sexual life, work, and social relationships. The data research was conducted using web-based search engines and/or various electronic research databases querying for all articles related to endometriosis and quality of life from the inception of the database up to February 2020. Endometriosis has not only physical but also psychological effects, causing depression, anxiety, and compromising social relationships. Furthermore, endometriosis negatively impacts sexual life and social relationships. At last, the economic burden of endometriosis should not be underestimated, both individually and for the community, as this pathology leads to a loss of productivity at work and large use of health resources. Thus, endometriosis-related symptoms control women’s lives compromising the quality of life in all aspects. In this review, we summarized the impact of endometriosis on various aspects of women’s lives.

Verified
Journal Article
Open access
PDF file
PGPierluigi Giampaolino
Pierluigi Giampaolino
VFVirginia Foreste
Virginia Foreste
CFClaudia Di Filippo
Claudia Di Filippo
AGAlessandra Gallo
Alessandra Gallo
Antonio MercorioAntonio Mercorio
Antonio Mercorio
Luigi Della CorteLuigi Della Corte
Luigi Della Corte
Polycystic ovary syndrome (PCOS) is a complex and heterogeneous endocrine disease. The hypothesis that alterations in the microbiome are involved in the genesis of PCOS has been postulated. Aim of this review is to summarize the available literature data about the relationship between microbiome and PCOS. A search on PubMed and Medline databases was performed from inception to November 20Most of evidence has focused on the connection of intestinal bacteria with sex hormones and insulin-resistance: while in the first case, a relationship with hyperandrogenism has been described, although it is still unclear, in the second one, chronic low-grade inflammation by activating the immune system, with increased production of proinflammatory cytokines which interfere with insulin receptor function, causing IR (Insulin Resistance)/hyperinsulinemia has been described, as well as the role of gastrointestinal hormones like Ghrelin and peptide YY (PYY), bile acids, interleukin-22 and Bacteroides vulgatus have been highlighted. The lower genital tract microbiome would be affected by changes in PCOS patients too. The therapeutic opportunities include probiotic, prebiotics and synbiotics, as well as fecal microbiota transplantation and the use of IL-22, to date only in animal models, as a possible future drug. Current evidence has shown the involvement of the gut microbiome in PCOS, seen how humanized mice receiving a fecal transplant from women with PCOS develop ovarian dysfunction, immune changes and insulin resistance and how it is capable of disrupting the secondary bile acid biosynthesis. A future therapeutic approach for PCOS may involve the human administration of IL-22 and bile acid glycodeoxycholic acid.

1 May 2019 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
PGPierluigi Giampaolino
Pierluigi Giampaolino
ASAttilio Di Spiezio Sardo
Attilio Di Spiezio Sardo
AMAntonio Mollo
Antonio Mollo
ARAntonio Raffone
Antonio Raffone
ATAntonio Travaglino
Antonio Travaglino
GBGiuseppe Bifulco
Giuseppe Bifulco

Verified
Journal Article
Open access
PDF file
Giuseppe GulloGiuseppe Gullo
Giuseppe Gullo
AEAndrea Etrusco
Andrea Etrusco
Gaspare CucinellaGaspare Cucinella
Gaspare Cucinella
APAntonino Perino
Antonino Perino
VCVito Chiantera
Vito Chiantera
Giovanni BuzzaccariniGiovanni Buzzaccarini
Giovanni Buzzaccarini
Endometrial cancer (EC) is a deleterious condition which strongly affects a woman’s quality of life. Although aggressive interventions should be considered to treat high-grade EC, a conservative approach should be taken into consideration for women wishing to conceive. In this scenario, we present an overview about the EC fertility-sparing approach state of art. Type I EC at low stage is the only histological type which can be addressed with a fertility-sparing approach. Moreover, no myometrium and/or adnexal invasion should be seen, and lymph-vascular space should not be involved. Regarding the pharmaceutical target, progestins, in particular medroxyprogesterone acetate (MPA) or megestrol acetate (MA), are the most employed agent in conservative treatment of early-stage EC. The metformin usage and hysteroscopic assessment is still under debate, despite promising results. Particularly strict and imperious attention should be given to the follow-up and psychological wellbeing of women, especially because of the double detrimental impairment: both EC and EC-related infertility consequences.

1 August 2020 in Gland Surgery
Verified
Journal Article
Open access
PDF file
PGPierluigi Giampaolino
Pierluigi Giampaolino
VFVirginia Foreste
Virginia Foreste
LCLuigi Della Corte
Luigi Della Corte
CFClaudia Di Filippo
Claudia Di Filippo
GIGiuseppe Gabriele Iorio
Giuseppe Gabriele Iorio
GBGiuseppe Bifulco
Giuseppe Bifulco
Ovarian cancer is frequently diagnosed at an advanced stage and a fraction of these patients fail to respond to primary therapy and relapses in 70% of cases. On account of the high recurrence probability and the poor outcomes after recurrence, there is an urgent need to predict progression as early as possible and thus found the strategies to detect and prevent a recurrence. Considering that biomarkers have contributed to the management of ovarian cancer by distinguishing benign and malignant pelvic masses and monitoring response to treatment, in this review, we aim to discuss the latest evidence reported in the literature about the use of biomarkers to detect OC recurrence. In detail, we summarized all the evidence of the most quoted biomarkers like HE4, osteopontin, mesothelin (MSLN), Folate receptor α (FOLR1), paraneoplastic antigens, miRNA, cancer stem cells (CSCs) and a combination of them to evaluate their role as prognostic biomarkers for ovarian cancer recurrence.

3 August 2018 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
ASAnna Sansone
Anna Sansone
NRNicoletta De Rosa
Nicoletta De Rosa
PGPierluigi Giampaolino
Pierluigi Giampaolino
MGMaurizio Guida
Maurizio Guida
Antonio Simone LaganàAntonio Simone Laganà
Antonio Simone Laganà
CCCostantino Di Carlo
Costantino Di Carlo